Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors

Ee Lyn Lim, …, Rahul Roychoudhuri, Klaus Okkenhaug

JCI Insight. 2018;3(11):e120626. https://doi.org/10.1172/jci.insight.120626.

Multiple modes of immunosuppression restrain immune function within tumors. We previously reported that phosphoinositide 3-kinase δ (PI3Kδ) inactivation in mice confers resistance to a range of tumor models by disrupting immunosuppression mediated by regulatory T cells (Tregs). The PI3Kδ inhibitor idelalisib has proven highly effective in the clinical treatment of chronic lymphocytic leukemia and the potential to extend the use of PI3Kδ inhibitors to nonhematological cancers is being evaluated. In this work, we demonstrate that the antitumor effect of PI3Kδ inactivation is primarily mediated through the disruption of Treg function, and correlates with tumor dependence on Treg immunosuppression. Compared with Treg-specific PI3Kδ deletion, systemic PI3Kδ inactivation is less effective at conferring resistance to tumors. We show that PI3Kδ deficiency impairs the maturation and reduces the capacity of CD8+ cytotoxic T lymphocytes (CTLs) to kill tumor cells in vitro, and to respond to tumor antigen–specific immunization in vivo. PI3Kδ inactivation antagonized the antitumor effects of tumor vaccines and checkpoint blockade therapies intended to boost the CD8+ T cell response. These findings provide insights into mechanisms by which PI3Kδ inhibition promotes antitumor immunity and demonstrate that the mechanism is distinct from that mediated by immune checkpoint blockade.

Find the latest version:

https://jci.me/120626/pdf
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors

Ee Lyn Lim,1 Fiorella M. Cugliandolo,1 Dalya R. Rosner,1 David Gyori,1 Rahul Roychoudhuri,1 and Klaus Okkenhaug1,2

1Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, United Kingdom. 2Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.

Introduction

Modulation of the immune response as a therapeutic strategy for cancer has proven to be a successful approach in some cancers. Studies using checkpoint blockade antibodies against cytotoxic T lymphocyte antigen 4 (CTLA-4) or the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have focused on the enhancement of CD8+ T cell activity (1–3). Anti–CTLA-4 antibody therapy has additionally been reported to deplete regulatory T cells (Tregs) in some contexts (4). We previously reported that inactivation of phosphoinositide 3-kinase δ (PI3Kδ), a central signaling component in leukocytes, conferred tumor resistance to a variety of tumor types, and that this protective effect could be explained by a key role for PI3Kδ in Tregs (5). The PI3Kδ pathway is engaged by the T cell receptor (TCR), the interleukin 2 (IL-2) receptor, and costimulatory receptors, and its inhibition could equally influence the effector immune response required for tumor clearance (6, 7). The challenge, therefore, is to define conditions that optimize the beneficial effect of PI3Kδ inhibition on Tregs while minimizing adverse effects on effector T cell (Teff) populations during antitumor immune responses. The PI3Kδ inhibitor idelalisib has been approved for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (8, 9). In these B cell cancers, PI3Kδ plays an important cell-intrinsic role, but may also affect cells in the tumor microenvironment (10, 11). To fully realize the potential of PI3Kδ inhibitors and for the optimal design of patient stratification and combinatorial therapies, it is imperative to further elucidate the impact of PI3Kδ inhibition on tumor immunity.

In this report, we show that the efficacy of PI3Kδ inactivation in restricting tumor growth correlates with the dependence of the specific tumor on Treg-mediated immunosuppression. Using ovalbumin-expressing (OVA-expressing) derivatives of cell lines to enable specific characterization of tumor antigen–specific CD8+ T cells, we found that the EL4-OVA lymphoma and MC38-OVA colon carcinoma were impaired in growth upon both Treg depletion and Treg-specific PI3Kδ deletion, but the Lewis lung carcinoma (LLC-OVA) was
unaffected in either condition. However, MC38-OVA tumors showed no growth reduction in mice with systemic PI3Kδ inactivation. We found that PI3Kδ-deficient CD8+ T cells had defects in maturation and cytotoxicity in vitro, and were impaired in their response to *Listeria monocytogenes* immunization in vivo. Furthermore, anti–CTLA-4 and anti–PD-L1 treatments failed to synergize with, and were indeed antagonized by, the loss of PI3Kδ function in host cells.

**Results**

**Efficacy of PI3Kδ deletion in restricting tumor growth correlates with tumor dependence on Treg-mediated immunosuppression.** We sought to determine the dependence of the different tumor models on Treg-mediated immunosuppression by transiently depleting Tregs from tumor-bearing mice. For these experiments we used the following tumor lines expressing OVA as a model antigen: EL4-OVA, MC38-OVA, or LLC-OVA (see Supplemental Figure 1 for characterization of immune cell infiltrates in each of these tumors; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.120626DS1). Foxp3DTR mice, along with C57BL/6 controls, were implanted with EL4-OVA, MC38-OVA, or LLC-OVA tumors; all mice were then treated with diphtheria toxin (DTx) on days 3, 7, and 10 after tumor injection. Administration of DTx reduced the proportion of CD4+ Foxp3+ Tregs among splenic lymphocytes by 65% 24 hours after injection, with near-complete recovery by 4 days after injection, i.e., prior to the next dose (Figure 1A).

Only in EL4-OVA tumors did we observe a significant reduction in Tregs after DTx administration, while LLC-OVA and MC38-OVA tumors showed no decrease at the time of tumor collection (Figure 1B). These differences may reflect the fact that the EL4-OVA tumors were collected 14 days after implantation, just 4 days after the last dose of DTx, whereas the LLC-OVA and MC38-OVA tumors were allowed to grow for 18 and 24 days, respectively, at which point Tregs were more likely to have recovered (12).

Nevertheless, transient Treg depletion led to reduced growth of EL4-OVA and MC38-OVA tumors, whereas LLC-OVA tumor growth was not affected (Figure 1C). These data indicated that Tregs were a non-redundant component of immunosuppression in EL4-OVA and MC38-OVA tumors, whereas LLC-OVA tumors likely relied on other factors to evade immune attack.

These results were mirrored in mice with a Treg-specific deletion of PI3Kδ (Figure 1D). As has been previously reported with the parental tumor EL4 (5), FYC-PI3Kδfl mice showed much reduced growth of EL4-OVA tumors compared with WT or PI3KδD910A mice (Figure 1D and Supplemental Figure 2). Similarly, FYC-PI3Kδfl mice were resistant to MC38-OVA tumors. By contrast, LLC-OVA tumors grew at the same rate in FYC-PI3Kδfl mice compared with WT controls. The data confirm that the antitumor effect of PI3Kδ deficiency is exerted through a loss of Treg suppressive function, in a manner that mimics Treg depletion, such that its efficacy correlates with the dependence of the tumor on Treg immunosuppression.

**Systemic PI3Kδ inactivation negates antitumor effect of Treg dysfunction in MC38-OVA tumors.** In PI3KδD910A mice, bearing a kinase-inactivating point mutation in PI3Kδ, EL4-OVA tumors were significantly reduced in growth, in a similar manner to mice with Treg-specific PI3Kδ deletion (Figure 1E and Supplemental Figure 2). LLC-OVA tumors exhibited no difference in growth regardless of the systemic nature of PI3Kδ inactivation. However, in contrast to Treg-specific deletion, systemic inhibition of PI3Kδ did not result in reduced growth of MC38-OVA cells.

We determined that the unresponsiveness of MC38-OVA tumors to PI3Kδ inactivation was not due to an imperviousness of MC38-OVA tumor–infiltrating Tregs to a loss of PI3Kδ activity. Indeed, a decrease in infiltrating Tregs in PI3Kδ-deficient mice was observed only in MC38-OVA tumors, and not in EL4-OVA or LLC-OVA tumors (Figure 1F). This implies an additional effect of PI3Kδ inactivation, which can negate the beneficial antitumor effects of PI3Kδ loss in Tregs. We considered CD8+ T cells to be the most likely culprit.

**In vitro cytotoxicity assay shows differential killing in different tumor cells, with a consistent reduction of cytotoxicity in PI3KδD910A CD8+ T cells.** As a functional test for CD8+ T cells under PI3Kδ inactivation, a cytotoxicity assay was used to measure OT-I CD8+ T cell killing of tumor cells expressing the cognate antigen OVA (see Methods section for experimental setup). Figure 2A shows an example of the flow cytometric readout from this assay, showing, from left to right, a near-complete clearance of green (OVA-expressing) tumor cells by WT OT-I CD8+ T cells, a moderate reduction of green cells by PI3KδD910A OT-I CD8+ T cells, and the original ratio of green and orange (parental) cells incubated without CD8+ T cells.

WT OT-I CD8+ T cells showed greater cytotoxic efficiency than PI3Kδ-inactivated OT-I CD8+ T cells in assays with EL4-OVA/EL4 cells (consistent with previous results), MC38-OVA/MC38 cells, or LLC-OVA/LLC cells (Figure 2B). While PI3KδD910A OT-I CD8+ T cells were less effective than WT OT-I cells...
Figure 1. Deletion of phosphoinositide 3-kinase δ (PI3Kδ) in regulatory T cells (Tregs) mimics the effects of Treg depletion, but systemic PI3Kδ inactivation is less effective. (A) Diphtheria toxin (DTx) was administered i.p. on days 3, 7, and 10 after s.c. tumor injection into the flank on day 0 (n = 6). EL4-OVA, MC38-OVA, and LLC-OVA tumors were removed on days 14, 24, and 18 after implantation, respectively. Proportions of Tregs in the blood of non–tumor-bearing mice (n = 2) were measured 24 hours after administration, and again immediately before the subsequent dose. (B) Proportion of tumor-infiltrating Tregs in the EL4-OVA, MC38-OVA, and LLC-OVA tumors at the time of collection. (C) Masses of EL4-OVA, MC38-OVA, and LLC-OVA tumors removed from WT or Foxp3 DTR mice as described in A. (D) Masses of EL4-OVA, MC38-OVA, and LLC-OVA tumors removed from WT or Foxp3 DTR mice as described in A.
WT or Foxp3\(^{\text{D}910\text{A}}\)-PI3K\(^{\text{D}910\text{A}}\) mice. (E) Masses of EL4-OVA \((n = 10)\), MC38-OVA \((n = 8)\), and LLC-OVA \((n = 8)\) tumors in WT or PI3K\(^{\text{D}910\text{A}}\) mice. (F) Proportion of tumor-infiltrating Foxp3\(^{+}\) Tregs in WT or PI3K\(^{\text{D}910\text{A}}\) mice; representative FACS plots of tumor-infiltrating lymphocytes are shown. Statistical significance was determined by multiple \(t\) tests with Holm-Sidak correction (B and F) or Mann-Whitney test (C, D, and E). *\(P < 0.05\); **\(P < 0.01\); ***\(P < 0.001\). n.s., not significant.

in eliminating target cells, they were nonetheless capable of a substantial amount of cell killing, especially when provided with EL4-OVA targets. Both WT and PI3K\(^{\text{D}910\text{A}}\) OT-I CD8\(^{+}\) T cells were less efficient at killing MC38-OVA cells than EL4-OVA cells, and were least efficient at eliminating LLC-OVA cells.

The influence of target antigen affinity on OT-I CD8\(^{+}\) T cell cytotoxicity was tested with a panel of SIINFEKL peptide variants, modified from the native peptide to give varying binding affinities for the OT-I TCR (13). EL4 cells were pulsed with 10 nM SIINFEKL or its variants (SAINFEKL, A2; SIQFEKL, Q4; SIITFEKL, T4; SIIVFEKL, V4; SIYNFEKL, Y3), then stained green and plated with untreated EL4 cells, in the same way as EL4-OVA cells were handled above. Small variations in antigen affinity did not result in significant changes in the efficiency of OT-I CD8\(^{+}\) T cell killing, with or without functional PI3K\(^{\text{D}910\text{A}}\) (Figure 2C) — even in EL4 cells presenting SIITFEKL (T4) peptide, which stimulated weaker proliferation than the A2, Q4, or Y3 peptides (13). SIIVFEKL (V4)-presenting EL4 cells were killed less effectively by WT OT-I T cells and not at all by PI3K\(^{\text{D}910\text{A}}\) OT-I T cells.

We previously reported that pharmacological inhibition of PI3K\(^{\text{D}910\text{A}}\) during the maturation phase of WT OT-I CD8\(^{+}\) T cells resulted in a defect in cytotoxicity equivalent to that seen in PI3K\(^{\text{D}910\text{A}}\) cells (5). We therefore hypothesized that PI3K\(^{\text{D}910\text{A}}\) OT-I CD8\(^{+}\) T cells might display an altered maturation profile after stimulation in vitro. WT and PI3K\(^{\text{D}910\text{A}}\) OT-I CD8\(^{+}\) T cells were cultured together with WT bone marrow–derived dendritic cells pulsed with SIINFEKL peptide, and expression of activation markers measured at 24-hour intervals (Figure 2D). While WT OT-I CD8\(^{+}\) T cells rapidly downregulated CD62L expression upon stimulation, PI3K\(^{\text{D}910\text{A}}\) cells did not show a similar change, maintaining high levels of CD62L expression throughout the culture duration; this could represent an obstacle for the cells to exit lymphoid organs upon activation in vivo (14).

PI3K\(^{\text{D}910\text{A}}\) OT-I CD8\(^{+}\) T cells also expressed less granzyme A than their WT counterparts, while granzyme B expression was similar (Figure 2D). Reduced expression of granzymes A and B was observed in PI3K\(^{\text{D}910\text{A}}\) tumor-infiltrating CD8\(^{+}\) T cells from LLC-OVA and MC38-OVA tumors, respectively (Figure 2E), showing that the defective maturation of PI3K\(^{\text{D}910\text{A}}\) CD8\(^{+}\) T cells in vitro may be equally relevant in the tumor environment. However, the reduction of granzyme expression was variable and modest — intratumoral CD8\(^{+}\) T cells showed no difference in levels of granzyme A in MC38-OVA, or of granzyme B in LLC-OVA, or of either granzymes A or B in EL4-OVA.

Immunization with OVA-expressing L. monocytogenes revealed a reduced ability of PI3K\(^{\text{D}910\text{A}}\) CD8\(^{+}\) T cells to respond to stimulation. As a measure of the CD8\(^{+}\) T cell response towards a tumor-specific antigen, OVA-specific CD8\(^{+}\) T cells from EL4-OVA, MC38-OVA, and LLC-OVA tumors were detected using the MHC class I:SIINFEKL oligomers (Figure 3A). EL4-OVA tumors had a relatively low proportion of CD8\(^{+}\) T cells within the tumor immune infiltrate, of which a small fraction (~5%) were specific for OVA. MC38-OVA tumors contained a higher proportion of CD8\(^{+}\) T cells, but the OVA-specific response remained at a similarly low level to that induced by EL4-OVA tumors. LLC-OVA tumors were infiltrated with a relatively high proportion of CD8\(^{+}\) T cells. Most strikingly, approximately 30% of these infiltrating CD8\(^{+}\) T cells expressed a TCR specific for OVA (representative plots shown in Figure 3A). As was the case for the other tumor models, the fraction of OVA-specific CD8\(^{+}\) T cells within LLC-OVA tumors was not altered in PI3K\(^{\text{D}910\text{A}}\)-deficient mice in comparison with WT.

To assess the ability of OVA-specific CD8\(^{+}\) T cells in these mice to mount a cytotoxic response against the OVA-expressing tumor, WT and PI3K\(^{\text{D}910\text{A}}\) mice bearing LLC-OVA tumors were immunized with attenuated L. monocytogenes — either expressing OVA (LM-OVA) or an irrelevant antigen YFP (LM-YFP) — 3 days after tumor implantation (Figure 3B). Blood was obtained from the mice 7 days after immunization, and assessed for the presence of anti-OVA response. WT mice mounted a strong CD8\(^{+}\) T cell response to LM-OVA, whereas in PI3K\(^{\text{D}910\text{A}}\) mice this response was detectable but significantly reduced.

WT mice receiving the LM-OVA immunization showed a reduction in tumor growth compared with PI3K\(^{\text{D}910\text{A}}\) mice (Figure 3C), accompanied by an increase in the fraction of OVA-specific CD8\(^{+}\) T cells within the tumor (Figure 3D). By contrast, LLC-OVA–bearing PI3K\(^{\text{D}910\text{A}}\) mice immunized with LM-OVA showed no increase in tumor-infiltrating OVA-specific CD8\(^{+}\) T cells. The protection of the WT mice
Figure 2. PI3Kδ(D910A) CD8+ T cells show functional defects. In vitro assays were conducted with 3 biological replicates. (A) CD8+ T cell cytotoxic capacity was measured in an in vitro killing assay, using tumor cells expressing ovalbumin (OVA) protein (stained with CMFDA CellTracker Green) as targets for in vitro-stimulated OT-I CD8+ T cells, and parental tumor cells (stained with CMRA CellTracker Orange) as controls. Representative FACS plots shows EL4-OVA and...
was OVA dependent, since mice that received LM-YFP did not show reduced tumor growth despite increased CD8⁺ T cell infiltration. These results reveal a defect in the ability of PI3KδD910A CD8⁺ T cells to respond to external stimuli that enhance antitumor responses, suggesting a more pronounced defect in CD8⁺ T cells than previously appreciated.

**PI3Kδ inactivation antagonized enhancement of Teff responses when combined with checkpoint blockade therapies.** We hypothesized that the relief of tumor immunosuppression brought about by PI3Kδ inactivation could be fully exploited by strengthening the weakened CD8⁺ T cell response, using other established cancer immunotherapies in combination. Antibody therapies against CTLA-4, and against the PD-1/PD-L1 signaling axis, are both in use in the clinic, having achieved remarkable success in the treatment of advanced melanoma (15–18). Both approaches aim to block the checkpoint signals that attenuate the function of activated Teffs, thus releasing Teffs from negative feedback control (19). PD-1/PD-L1 blockade has previously been shown to effectively reduce growth of EL4-OVA, MC38, and LLC tumors (20–22), while anti–CTLA-4 has not been as successful, at least as a monotherapy in tumors lacking expression of a strongly immunogenic antigen (23–25).

PI3KδD910A mice were injected with either LLC-OVA or MC38-OVA tumors, and treated with 3 doses of antibody against CTLA-4 or PD-L1 (Figure 4A). Both tumor types were effectively treated with anti–CTLA-4 in WT mice, showing greatly reduced growth compared with mice treated with isotype control. In the absence of host PI3Kδ activity, however, anti–CTLA-4 treatment had negligible effect on tumor growth (Figure 4, B and C). LLC-OVA tumors did not respond to anti–PD-L1 treatment, whether in WT or PI3KδD910A mice (Figure 4D). In MC38-OVA tumors, a similar result was obtained with anti–PD-L1 antibody treatment as with anti–CTLA-4 — while tumor growth was restricted in WT mice, in PI3Kδ-inactivated mice the antibody treatment failed to have a significant effect (Figure 4E). The expression of a number of activation or functional markers was measured on CD8⁺ T cells and Tregs in MC38-OVA tumors, but we found no clear reason why PI3KδD910A CD8⁺ T cells should be impaired beyond rescue by combination therapy (Supplemental Figure 3). These results suggest that host PI3Kδ function is required for the efficacy of anti–CTLA-4 and anti–PD-L1 treatment, and that PI3Kδ inactivation does not synergize with, but rather abrogates the antitumor effects achieved with the checkpoint blockade therapies.

**Discussion**

We have demonstrated that PI3Kδ inactivation attenuates Treg suppressive function, which can unleash a potent antitumor immune response, conditional upon the dependence of the specific tumor type on Treg immunosuppression. However, loss of PI3Kδ activity in CD8⁺ cells impairs the effector immune response, which can negate the beneficial effects of Treg dysfunction, and block the efficacy of checkpoint blockade therapies.

A striking observation that emerged early in this study was the complete independence of LLC-OVA tumors from Tregs to provide protection against immune attack, such that selective depletion of Tregs had no impact on tumor progression. This result strongly underscores the idea that the immune response to different tumors can be highly distinct, which dictates their response to each therapeutic strategy. LLC tumors are also known to derive immune suppression from cancer-associated fibroblasts (CAFs) (26). MC38 tumors have been found to be dependent on TAMs for immune evasion (27), suggesting redundancy between myeloid and Treg-mediated suppression.

Furthermore, the relative susceptibility of the EL4-OVA, MC38-OVA, and LLC-OVA cell lines to CD8⁺ T cell cytotoxicity indicate cell-intrinsic differences, for example, in the ability to degrade granzyme B (28). While these differences may be difficult to translate directly to an in vivo setting, they may be important in explaining why the impaired cytotoxicity of PI3Kδ-inactivated CD8⁺ T cells was still sufficient to eliminate EL4-OVA tumors in PI3KδD910A mice, whereas this reduced CD8⁺ T cell function could not overcome even a compromised Treg suppression to kill MC38-OVA tumors.
The effects of PI3Kδ deficiency on effector immune cells have previously been discussed in several reports, with somewhat conflicting conclusions. Putz et al. found that PI3Kδ−/− CD8+ T cells had defective expression of genes critical to cytotoxic function, and accordingly were impaired in their ability to eliminate tumor cells (29). We have also reported that PI3Kδ-inactivated mice have a reduced CD8+ T cell response to *L. monocytogenes* infection (30). On the other hand, it was recently reported that PI3Kδ inhibition selectively affected proliferation and viability in Tregs over conventional CD4+ T cells, thus conferring a therapeutic advantage in combination with a tumor peptide vaccine (31). The relative significance of CD8+ T cells and conventional CD4+ T cells in the antitumor response likely varies by tumor type, but we show here that a reduction in CD8+ T cell function is in some cases sufficient to abrogate the advantages of Treg impairment. This needs to be considered as PI3Kδ inhibitors are being developed for immunotherapy.

**Figure 3. Defects in PI3Kδ-deficient CD8+ T cell response abrogate antitumor effect of LM-OVA immunization.** (A) OVA-specific CD8+ T cell responses in the tumor immune infiltrate (*n* = 6). Representative plots show MHC class I:SIINFEKL dextramer staining on tumor-infiltrating CD8+ T cells in LLC-OVA tumors. Differences between WT and PI3KδD910A mice were not significant in all tumor types. (B) LLC-OVA tumor-bearing mice were immunized with attenuated LM-OVA or LM-YFP (both 10⁶ CFU) 3 days after tumor implantation. CD8+ T cell responses against the OVA antigen were measured in the blood 7 days after immunization (*n* = 6). (C) Tumor growth measured in WT and PI3KδD910A mice receiving PBS control, LM-YFP, or LM-OVA immunization (*n* = 12, combined 2 experiments). (D) OVA-specific CD8+ T cell response in the tumor in response to immunization measured in WT and PI3KδD910A mice (*n* = 6). Statistical significance determined by multiple *t* tests with Holm-Sidak correction (A and C) or 2-way ANOVA with Tukey’s multiple comparison (B and D). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. n.s., not significant.
Where idelalisib is already administered as a treatment for CLL, reports of immune-mediated adverse events provide some insight to the effect of PI3Kδ inhibition on the human immune response (32). Both colitis and hepatotoxicity in idelalisib-treated patients are characterized by increased infiltration of T lymphocytes, suggesting an enhancement of the effector immune response (33, 34). Reductions in Treg numbers have not been consistently observed in these reports, but considering the imperfect correlation between numbers and function, as well as the upregulation of Foxp3 in human Teffs upon activation, the specific effects of PI3Kδ inhibition on the human Treg response remain to be determined.

Our results highlight that the mechanism by which PI3Kδ inhibition leads to enhanced antitumor responses is distinct, and not necessarily complementary to that elicited using antibodies against CTLA-4 or PD-L1. Both of these therapies are intended to enhance the CD8+ T cell response, but were unable to enhance or compensate for the effects of PI3Kδ inhibition. Mechanistically, checkpoint inhibitors may act in part by enhancing PI3K activity in Teffs. Hence, signaling through CTLA-4 antagonizes Akt activity through the type II serine/threonine phosphatase PP2A, whereas PD-1 can activate SHP1 to inhibit CD28-dependent PI3K activity (35–38). Thus, PI3Kδ inhibition may antagonize the signaling pathway unleashed by these checkpoint inhibitors.

**Figure 4.** PI3Kδ-deficient CD8+ T cells fail to respond to checkpoint blockade. (A) Mice bearing LLC-OVA or MC38-OVA tumors received intravenous injections of antibodies against cytotoxic T lymphocyte antigen 4 (CTLA-4) or programmed death ligand 1 (PD-L1) on days 3, 6, and 10 after tumor injection (treatment of LLC-OVA tumor with anti–PD-L1 was performed on days 2, 5, and 9 after tumor injection) (n = 6). (B and C) Anti–CTLA-4 antibody treatment of LLC-OVA (B) and MC38-OVA (C) tumors in WT and PI3KδD910A mice: no significant change was observed in tumor-infiltrating CD8+ T cells. (D and E) Anti–PD-L1 antibody treatment of LLC-OVA (D) and MC38-OVA (E) tumors in WT and PI3KδD910A mice. Only 2 WT tumors were available for analysis, and no significant changes were found in the CD8+ infiltrate of these tumors. Statistical significance determined by Mann-Whitney test between antibody-treated and control groups. *P < 0.05; **P < 0.01.
The antagonistic relationship between PI3Kδ inhibition and checkpoint blockade does not necessarily preclude combining the 2 therapeutic modalities. Others have reported synergy in the treatment of MC38 tumors with a combination of a small-molecule PI3K inhibitor and anti–PD-1 (39), apparently in contrast with the results shown here. Administration of a PI3K inhibitor starting after the tumor becomes palpable may provide a crucial window of time for CD8+ T cells to encounter tumor antigens and become activated before PI3Kδ signaling is shut down. We previously showed an important role for PI3Kδ in the early phase of CD8+ T cell maturation, whereas it was no longer necessary for fully activated CD8+ T cells to kill target cells (5). Intermittent dosing with PI3K inhibitors, or dosing PI3K inhibitors sequentially with immune checkpoint inhibitors, may be strategies worth considering. In fact, the inhibition of PI3Kδ during the in vitro expansion of T cells subsequently used for adoptive cell therapy enhances tumor rejection in mice, potentially by expanding a subset of CD8+ T cells with stem cell–like properties that may allow for a more persistent attack on the tumors (40–42). The challenge therefore will be to harness this potential to enhance the durability of the CD8+ T cell response while inhibiting Treg-mediated suppression. Our accompanying report (27) suggests that rather than combining PI3Kδ inhibitors with agents that boost T cell costimulation, combinatorial targeting of suppressive cell populations, such as using PI3Kδ inhibitors to target Treg and CSF-1 inhibitors to target suppressive monocytes may be a better strategy, taking advantage of the multiple immune-suppressive mechanisms employed by cancers.

**Methods**

*Mice.* C57BL/6.Babr and B6.SJL.Babr (WT) mice were obtained from the breeding colonies in the Biological Services Unit, Babraham Institute. All other mice used in this study were maintained on a C57BL/6 background. p110δ5910A/D910A (PI3Kδ5910A) mice have an aspartic acid–to-alanine (D910A) point mutation in the p110δ catalytic domain, rendering it inactive (43). OT-I mice express a transgenic TCR (Vα2-Vβ5) specific for the OVA peptide SIINFEKL (OVA 257–264) presented by MHC class IA (H-2Kb) (44), and homogeneously express CD45.1. The OT-I transgenic TCR was crossed to a PI3Kδ-inactivated background, in the p110δ5910A × OT-I strain. Foxp3-YFP-Cre (FYC) mice express a YFP-Cre fusion protein reporter in Foxp3-expressing cells (45). These mice were crossed with a mouse strain harboring loxp sites flanking alleles 1–9 of the *Pik3cd* gene, such that p110δ was specifically deleted in Foxp3δ cells (FYC × p110δδ/δ strain) (5). Foxp3ΔTreg mice express the human DTx receptor and an eGFP reporter under the Foxp3 promoter, allowing specific depletion of Foxp3δ cells upon administration of DTx (46).

All mice were maintained under specific pathogen–free conditions in the Biological Services Unit, Babraham Institute. Mice were matched for age (8–14 weeks) and sex (balanced) in each experiment. Studies involving administration of treatment substances were blinded for tumor growth measurement. Where applicable, experimental group sizes are indicated by individual data points.

*Tumors.* EL4 and EL4-OVA (also known as EG7) cells were obtained from ATCC (47, 48). LLC cells were obtained from Douglas Fearon (Cancer Research UK Cambridge Institute, Cambridge, United Kingdom) along with the LLC-OVA derivative (26). MC38 and MC38-OVA cell lines were obtained from from Mark Smyth (QIMR Berghofer, Brisbane, Australia) (49, 50). Cells were maintained in culture in DMEM with high glucose and L-glutamine (GIBCO) containing 10% FCS (LabTech); EL4-OVA cultures were supplemented with 400 μg/ml G418 selection antibiotic (Melford Laboratories Ltd) from 48 hours after thawing. The adherent cell lines (LLC, LLC-OVA, MC38, and MC38-OVA) were dissociated from culture flasks using Cell Dissociation Buffer (GIBCO).

Suspensions of tumor cells were prepared in sterile PBS (in-house preparation). EL4-OVA or LLC-OVA cells (5 × 10⁶ each), or 2 × 10⁶ MC38-OVA cells, were administered by subcutaneous injection under inhaled anesthesia (isoflurane). When tumors became palpable (around day 8 after implantation for EL4-OVA tumors, or around day 10 for LLC-OVA and MC38-OVA tumors), tumor growth was monitored by caliper measurements every 2–3 days. Tumor volume (mm³) was calculated as length × width². Mice bearing EL4-OVA tumors were culled between 16 and 17 days after implantation, mice bearing LLC-OVA tumors between 20 and 22 days, and mice bearing MC38-OVA tumors between 24 and 28 days; where experimental schedules depart from this schedule (e.g., in cases of unexpectedly aggressive tumor growth) this is indicated in the relevant figure legend. Any mice bearing tumors that approached or exceeded the terminal size limit during the course of the study were culled and excluded from the study. A maximum of 1 g of tumor tissue per sample was processed on a gentleMACS Dissociator (Miltenyi Biotec) according to the ‘soft/medium tissue’ protocol from the Tumor Dissociation
controls used in these experiments were, respectively, polyclonal Syrian hamster IgG (Bio X Cell), and rat anti–PD-L1 antibody (clone 10F.9G2, Bio X Cell). The isotype-matched to ratios recorded in wells to which no CD8+ T cells were added.

δ PI3K (51). LM-OVA and LM-YFP (106 CFU per mouse) were administered intravenously in 100 μl of PBS as a negative control. Samples of blood (50 μl) were collected at 18 hours, the cells were resuspended in Cell Dissociation Buffer (GIBCO) containing 1 μg/ml DAPI. Once dissociated, samples were acquired on the Fortessa flow cytometer (Beckton Dickinson), recording CMRA on the 585/561 nm channel, CMFDA on 530/488 nm, and DAPI on 450/405 nm. Fixable Viability Dye eFluor 780 (eBioscience) was added to the surface stain solution at a 1:3,000 dilution. Samples were acquired on BD Fortessa analyzers in the Babraham Institute Flow Core Facility. Data collected were analyzed using FlowJo software (Tree Star).

In vitro cytotoxicity assay. Splenocytes from OT-I and P13KδD910A × OT-I mice (n = 3 for each group) were stimulated with SIINFEKL peptide at 10 nM. After 48 hours, CD8+ T cells were isolated from the cultures by MACS negative selection (Miltenyi Biotec). The CD8+ T cells were returned to culture with daily supplement of recombinant human IL-2 (Glaxo-IMB), at a concentration of 20 ng/ml, for an additional 6 days. Parental tumor cells and OVA-expressing derivatives were stained with, respectively, CellTracker Orange CMRA and CellTracker Green CMFDA (Molecular Probes). Peptide-presenting EL4 cells were incubated with the OVA oligopeptide SIINFEKL, and 5 single-amino-acid variants — SAINFEKL, SIIQFEKL, SIITFEKL, SIIVFEKL, and SIYNFEKL (ProImmune ThinkPeptides) — at 10 nM for 1 hour. Each parental/OVA-expressing derivative pair (EL4 and EL4-OVA, LLC and LLC-OVA, and MC38 and MC38-OVA) (104 cells each), and 105 in vitro–activated CD8+ T cells were incubated together, giving a 1:1:10 mixture of orange-stained cells (parental), green-stained cells (OVA-expressing), and CD8+ T cells.

After 18 hours, the cells were resuspended in Cell Dissociation Buffer (GIBCO) containing 1 μg/ml DAPI. Once dissociated, samples were acquired on the Fortessa flow cytometer (Beckton Dickinson), recording CMRA on the 585/561 nm channel, CMFDA on 530/488 nm, and DAPI on 450/405 nm. Cytotoxic efficiency was calculated as a ratio of live (DAPI–), OVA-presenting cells (antigen-presenting target cells, green) over parental cells, which did not express the OT-I CD8+ target antigen (orange), normalized to ratios recorded in wells to which no CD8+ T cells were added.

In vitro CD8+ maturation assay. CD8+ T cells were isolated from spleens and lymph nodes of WT and P13KδD910A OT-I mice by MACS negative selection, and cultured together with WT bone marrow–derived dendritic cells that had been pulsed with 100 pM SIINFEKL peptide for 2 hours, at a 5:1 ratio. Cultures were maintained at approximately 3 × 106 cells/ml and supplemented with 20 ng/ml recombinant human IL-2 (Glaxo-IMB) daily from 48 hours onwards. Aliquots were taken at 24-hour intervals for flow analysis.

Vaccination with attenuated OVA-expressing L. monocytogenes. Tumor-bearing mice were inoculated with attenuated (ActA-) LM-OVA to induce a CD8+ T cell immune response to OVA, also expressed in tumor cells. The original stocks of attenuated LM-OVA, as well as a strain of LM expressing an irrelevant antigen (attenuated LM-YFP) were obtained from Hao Shen (University of Pennsylvania, Philadelphia, Pennsylvania, USA) (51). LM-OVA and LM-YFP (106 CFU per mouse) were administered intravenously in 100 μl, 3 days after tumor implantation, with attenuated LM-YFP as a control for non–antigen-specific immunization, and with PBS as a negative control. Samples of blood (50 μl) were obtained from each mouse at 7 days after inoculation, to confirm the presence of a CD8+ T cell response against OVA.

Checkpoint blockade treatment. WT and P13KδD910A tumor–bearing mice were treated with anti–CTLA-4 antibody (clone 9H10, Bio X Cell) and anti–PD-L1 antibody (clone 10F.9G2, Bio X Cell). The isotype controls used in these experiments were, respectively, polyclonal Syrian hamster IgG (Bio X Cell), and rat anti–PD-L1 (clone 10F.9G2, Bio X Cell). The isotype controls used in these experiments were, respectively, polyclonal Syrian hamster IgG (Bio X Cell), and rat anti–PD-L1 (clone 10F.9G2, Bio X Cell).
IgG2b (clone LTF-2, Bio X Cell) at a dose of 10 mg/kg, in a volume of 100 μl, separately calculated based on average weights of male and female mice in each cohort, on days 3, 6, and 10 after tumor implantation (administered by technicians in the Babraham Institute Biological Support Unit); where experimental schedules depart from this schedule this is indicated in the relevant figure legend.

**Statistics.** Statistical analyses of results were carried out using GraphPad Prism. Unless otherwise specified, the Mann-Whitney (2-tailed nonparametric t) test or multiple t tests (with Holm-Sidak correction for multiple comparison) was applied to assess significance, with P < 0.05 considered significant. Error bars presented in plots represent standard error of the mean (SEM). Any repeats of experiments are indicated in figure legends. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

**Study approval.** All protocols involving live animals were approved by the United Kingdom Home Office (PPL 70/7661) and Babraham Institute Animal Welfare and Ethics Review Board.

**Author contributions**
Experiments were performed by ELL, with contributions from FMC, DRR, and DG. RR and KO supervised the study. ELL and KO wrote the manuscript.

**Acknowledgments**
We are grateful for the expert assistance provided by Rachael Walker and Arthur Davis at the Flow Cytometry facility, and for the technical support from staff at the Biological Services Unit. E. L. Lim was supported by the Yousef Jameel Scholarship (Cambridge Trust). D. Gyori was funded by a grant from Karus Therapeutics Ltd. R. Roychoudhuri and K. Okkenhaug received institute support from Biotechnology and Biological Sciences Research Council (BBSRC) BBS/E/B/000C0407, -C0409, -C0427, and -C0428 and project grant BB/N007794/1. R. Roychoudhuri was supported by Wellcome Trust grant 105663/Z/14/Z. K. Okkenhaug was also supported by Wellcome Trust grant 095198/Z/10/Z.

Address correspondence to: Klaus Okkenhaug, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QF, United Kingdom. Phone: 44.1223.333726; Email: ko256@cam.ac.uk.

ELL’s present address is: Immunology Frontier Research Center, Osaka University, Osaka, Japan.

1. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med.* 2002;8(9):793–800.
2. Maker AV, Attaia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. *J Immunol.* 2005;175(11):7746–7754.
3. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *Proc Natl Acad Sci USA.* 2010;107(9):4275–4280.
4. Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J Exp Med.* 2013;210(9):1695–1710.
5. Ali K, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. *Nature.* 2014;510(7505):407–411.
6. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. *Nat Rev Immunol.* 2003;3(4):317–330.
7. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. *Annu Rev Immunol.* 2013;31:675–704.
8. Furman RR, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med.* 2014;370(11):997–1007.
9. Gopal AK, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med.* 2014;370(11):1008–1018.
10. Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: Impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. *Cancer Discov.* 2016;6(10):1090–1105.
11. Fruman DA, Chou H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. *Cell.* 2017;170(4):605–635.
12. Pierson W, et al. Antia apoptotic McI-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells. *Nat Immunol.* 2013;14(9):959–965.
13. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. *Nature.* 2009;458(7235):211–214.
14. Finlay DK, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. *J Exp Med.* 2012;209(13):2441–2453.
15. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med.* 2010;363(8):711–723.
16. Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med.* 2013;369(2):122–133.
17. Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med.* 2015;372(26):2521–2532.
18. Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol.* 2015;16(4):375–384.
19. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
20. Taylor A, Rothstein D, Rudd CE. Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy. Cancer Res. 2018;78(3):706–717.
21. Homet Moreno B, et al. Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol Res. 2016;4(10):845–857.
22. Nagato T, Lee YR, Harabuchi Y, Celis E. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8+ T-cell responses against established tumors. Clin Cancer Res. 2014;20(5):1223–1234.
23. Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockade of CTLA-4 signaling. Cancer Lett. 2006;231(2):247–256.
24. Kocak E, et al. Combination therapy with anti-CTLA-4 antibody and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006;66(14):7276–7284.
25. Lesterhuis WJ, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE. 2013;8(4):e61895.
26. Kraman M, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827–830.
27. Gyori D, et al. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Insight. 2018;3(11):e120631.
28. Baginska J, et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci USA. 2013;110(43):17450–17455.
29. Putz EM, et al. PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS One. 2012;7(7):e40852.
30. Pearce VQ, Bouabe H, MacQueen AR, Carbonaro V, Okkenhaug K. PI3Kδ regulates the magnitude of CD8+ T cell responses after challenge with Listeria monocytogenes. J Immunol. 2015;195(7):3260–3217.
31. Kocak E, et al. Differential PI3Kδ signaling in CD4+ T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res. 2017;77(8):1892–1904.
32. Greenwell IB, Ip A, Cohen JB. PI3Kδ inhibitors: Understanding toxicity mechanisms and management. Oncoology (Williston Park, NY). 2017;31(11):821–828.
33. Lampson BL, et al. Idealisib given front-line treatment for chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195–203.
34. Yeung CC, et al. Pathological assessment of gastrointestinal biopsies from patients with idealisib-associated diarrhea colitis [published online ahead of print March 28, 2018]. Future Oncol. https://doi.org/10.2217/fon-2017-0528.
35. Parry RV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–9553.
36. Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol. 2013;33(16):3091–3098.
37. Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428–1433.
38. Kamphorst AO, et al. Rescue of exhausted CD8+ T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423–1427.
39. Koblash HK, et al. Abstract C103: The combination of PI3Kδ-selective inhibition and immunomodulation shows efficacy in solid tumor models. Mol Cancer Ther. 2015;14(12 Supplement 2):C103–C103.
40. Crompton JG, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015;75(2):296–305.
41. Bowers JS, et al. PI3Kδ inhibition enhances the antitumor fitness of adoptively transferred CD8+ T cells. Front Immunol. 2017;8:1221.
42. Abu Eid R, et al. Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3Kδ inhibition. Cancer Res. 2017;77(15):4135–4145.
43. Okkenhaug K, et al. Impaired B and T cell antigen receptor signaling in p110delta PI3-kinase mutant mice. Science. 2002;297(5583):1031–1034.
44. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. Pillars article: T cell receptor antagonist peptides induce positive selection. Cell. 1994. 76: 17–27. J Immunol. 2012;188(5):2046–2056.
45. Rubtsov YP, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546–558.
46. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8(2):191–197.
47. Gorer PA. Studies in antibody response of mice to tumour inoculation. Br J Cancer. 1950;4(4):372–379.
48. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988;54(6):777–785.
49. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinoen formation. Cancer Res. 1975;35(9):2434–2439.
50. Gilliliam S, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med. 2008;208(13):2965–2973.
51. Pearce EL, Shen H. Generation of CD8+ T cell memory is regulated by IL-12. J Immunol. 2007;179(4):2074–2081.